search for


Analysis of Prescribing Errors of Investigational Drugs in Oncology Clinical Trials
J. Kor. Soc. Health-syst. Pharm. 2019;36:366-373
Published online August 31, 2019;
© 2019 Korean Society of Health-System Pharmacists

Jin Young Moona,b,, Yeon Hong Leeb, Mi Hyung Leeb, Young Ju Kimb and Hye Sun Gwaka,†

College of Pharmacy and Division of Life and Pharmaceutical Sciences, Ewha Womans University, Seoul, 03760, Republic of Koreaa Department of Pharmacy, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, 10408, Republic of Koreab
Correspondence to: 곽혜선 Tel:02-3277-4376
Received April 27, 2019; Revised June 4, 2019; Accepted June 26, 2019.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Objective : Investigational drugs are often considered to be high-risk or hazardous medications. It is necessary to study medication errors in clinical trials. This study aimed at identifying the frequency and types of prescribing errors in oncology clinical trials.
Methods : We retrospectively analyzed investigational drug orders and pharmacist intervention records from December 2015 to February 2017 in the National Cancer Center.
Results : Among 12,387 investigational drug orders, 673 (5.43%) prescribing errors were detected by pharmacists.
Regarding the route of administration, the prescription error rate related to IV medications was higher than that of oral medications (7.23% vs. 4.34%). The most common prescribing error in IV medications were wrong medication kit number (164 cases, 48.52 %) followed by incorrect diluent (75 cases, 22.19%), wrong dose (70 cases, 20.71%), and omission of information (20 cases, 5.92%). Meanwhile, the most common prescribing error in oral medications were wrong medication kit number (119 cases, 35.52 %) followed by incorrect quantity (67 cases, 20.0%), wrong dose (58 cases, 17.31%), and incorrect treatment duration (45 cases, 13.43%).
Conclusions : This study provides the frequency and types of prescribing errors in oncology clinical trials. The pharmacist intervention may improve safety of investigational drug use.
Keywords : Pharmacist intervention, Prescribing error, Clinical trial

August 2019, 36 (3)